Pasithea Therapeutics Corp (KTTA)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Pasithea Therapeutics Corp chart...

About the Company

We do not have any company description for Pasithea Therapeutics Corp at the moment.

Exchange

NASDAQ

$0M

Total Revenue

15

Employees

$149M

Market Capitalization

-67.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $KTTA News

KTTA Pasithea Therapeutics Corp.

3mon ago, source: Seeking Alpha

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two ...

Pasithea Therapeutics Corp. Wt

28d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Pasithea Therapeutics begins U.S. trial for cancer treatment

1mon ago, source: Investing

SOUTH SAN FRANCISCO, Calif. - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, has announced the activation of four U.S. clinical trial sites for its Phase 1 ...

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

1mon ago, source: ADVFN

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative ...

United Therapeutics Corporation (UTHR)

3d ago, source: Yahoo Finance

United Therapeutics Corp (NASDAQ:UTHR) Chairperson & CEO Martine Rothblatt has sold 30,000 shares of the company on March 22, 2024, according to a recent SEC Filing. SILVER SPRING, Md.

KTTA Pasithea Therapeutics Corp.

5d ago, source: Seeking Alpha

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two ...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

1mon ago, source: ADVFN

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor ...

Pasithea Therapeutics begins U.S. trial for cancer treatment

1mon ago, source: Investing

SOUTH SAN FRANCISCO, Calif. - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, has announced the activation of four U.S. clinical trial sites for its Phase 1 study ...

Pasithea Therapeutics Corp KTTA

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pasithea Therapeutics Corp. (KTTA)

2mon ago, source: Yahoo Finance

and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation -- ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...